Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.

Date publication

juillet 2018

Journal

Arteriosclerosis, thrombosis, and vascular biology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Pr PETIT Jean-Michel , Pr VERGES Bruno , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Sberna AL, Petit JM, Degrace P, Demizieux L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30026275

Résumé

Treatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist, has been shown to reduce postprandial lipidemia, an important feature of diabetic dyslipidemia. However, the underlying mechanisms for this effect remain unknown. This prompted us to study the effect of liraglutide on the metabolism of ApoB48 (apolipoprotein B48).

Mots clés

apolipoprotein B-48, diabetes mellitus, hyperlipidemias, kinetics, liraglutide, period, postprandial

Référence

Arterioscler. Thromb. Vasc. Biol.. 2018 Jul 19;: